Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grainne Kerr

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Computational and Structural Biotechnology Journal|February 27, 2020
Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft modelsKathleen Sprouffske, Grainne Kerr, Cheng Li, et al.
ACS Pharmacology & Translational Science|February 22, 2021
Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance MechanismsVerena Apfel, Damien Begue, Valentina Cordo', et al.
Nature Communications|October 29, 2013
Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cellsOksana Voloshanenko, Gerrit Erdmann, Taronish D Dubash, et al.
Scientific Reports|November 19, 2020
Identification of the HECT E3 ligase UBR5 as a regulator of MYC degradation using a CRISPR/Cas9 screenLina Schukur, Tamara Zimmermann, Ole Niewoehner, et al.
Molecular Therapy. Methods & Clinical Development|October 27, 2021
Evaluation of two <i>in vitro</i> assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cellsMyriam Lemmens, Benoit Fischer, Michael Zogg, et al.
Oncotarget|March 28, 2020
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathwayCaroline Dafflon, Swann Gaulis, Louise Barys, et al.
Cancer Research|November 7, 2023
CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung CancerAnirudh Prahallad, Andreas Weiss, Hans Voshol, et al.
Cell Reports|March 24, 2023
Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitorsRalph Tiedt, Frederick J King, Christelle Stamm, et al.
Nature Medicine|December 19, 2018
Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR lossHuayang Liu, Javad Golji, Lauren K Brodeur, et al.
Nature|July 13, 2022
Structure of the MRAS-SHOC2-PP1C phosphatase complexZachary J Hauseman, Michelle Fodor, Anxhela Dhembi, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Computational and Structural Biotechnology Journal|February 27, 2020
Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft modelsKathleen Sprouffske, Grainne Kerr, Cheng Li, et al.
ACS Pharmacology & Translational Science|February 22, 2021
Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance MechanismsVerena Apfel, Damien Begue, Valentina Cordo', et al.
Nature Communications|October 29, 2013
Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cellsOksana Voloshanenko, Gerrit Erdmann, Taronish D Dubash, et al.
Scientific Reports|November 19, 2020
Identification of the HECT E3 ligase UBR5 as a regulator of MYC degradation using a CRISPR/Cas9 screenLina Schukur, Tamara Zimmermann, Ole Niewoehner, et al.
Molecular Therapy. Methods & Clinical Development|October 27, 2021
Evaluation of two <i>in vitro</i> assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cellsMyriam Lemmens, Benoit Fischer, Michael Zogg, et al.
Oncotarget|March 28, 2020
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathwayCaroline Dafflon, Swann Gaulis, Louise Barys, et al.
Cancer Research|November 7, 2023
CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung CancerAnirudh Prahallad, Andreas Weiss, Hans Voshol, et al.
Cell Reports|March 24, 2023
Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitorsRalph Tiedt, Frederick J King, Christelle Stamm, et al.
Nature Medicine|December 19, 2018
Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR lossHuayang Liu, Javad Golji, Lauren K Brodeur, et al.
Nature|July 13, 2022
Structure of the MRAS-SHOC2-PP1C phosphatase complexZachary J Hauseman, Michelle Fodor, Anxhela Dhembi, et al.
Pageof 3